La Jolla Pharmaceutical (NASDAQ: LJPC)
La Jolla Pharmaceutical Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
La Jolla Pharmaceutical Company Info
La Jolla Pharmaceutical Company is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics for chronic organ failure and cancer. GCS-100, the Company's lead product candidate, is a first-in-class inhibitor of galectin-3, a novel molecular target implicated in chronic organ failure and cancer. LJPC-501, the Company's second product candidate, is a natural peptide for the treatment of the hepatorenal syndrome.
News & Analysis
Here's Why La Jolla Pharmaceutical Has More Than Doubled Over the Last 2 Days
A mid-stage clinical trial has investors excited about the biotech's future.
Here's Why La Jolla Pharmaceutical Tumbled Today
The company provided preliminary operating results for 2018 and expectations for the year ahead.
Why La Jolla Pharmaceutical Is Tumbling Today
Shares drop off after the company reports second-quarter results that left investors wanting more.
Why Lumber Liquidators Holdings, Stamps.com, and La Jolla Pharmaceutical Slumped Today
The market soared, but these stocks got left behind. Find out why.
Here's Why La Jolla Pharmaceutical Shares Are Surging 12.5% Higher Today
The FDA surprised the biopharmaceutical with good news today.
Here's What's Causing Investors to Sell La Jolla Pharmaceutical Shares Today
The company's making progress toward an FDA decision on its lead drug candidate, but that's not enough to keep investors happy.
Here's Why La Jolla Pharmaceuticals Company Is Soaring
Shares jump after the company reports that the results from its ATHOS-3 study will be published in the New England Journal of Medicine.
Why La Jolla Pharmaceutical Company Shares Are Skyrocketing
The release of upbeat data from an important phase 3 trial has investors cheering.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.